Oleg Volchonok, MD
Gastroenterology · Philadelphia, PANPI 1275571945
Payments from drug & device makers
Across 718 payments — averaging $145.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Phathom Pharmaceuticals, Inc.$21K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Ironwood Pharmaceuticals, Inc$12K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$12K
- Redhill Biopharma Inc.$2K
- plus $8K from 27 others
What the payments were for
- Speaking & faculty fees$85,06182%
- Travel & lodging$3,4933%
- Food & beverage$15,16315%
- Education$2830%
- Gifts$3600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 170 | $35,720 |
| Phathom Pharmaceuticals, Inc. | 45 | $20,501 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $13,817 |
| Ironwood Pharmaceuticals, Inc | 39 | $12,036 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 108 | $11,630 |
| Redhill Biopharma Inc. | 16 | $2,499 |
| Gilead | 85 | $2,357 |
| Johnson & Johnson(3 entities) | 37 | $994 |
| Ardelyx, Inc. | 43 | $793 |
| Nestle Healthcare Nutrition Inc. | 1 | $750 |
| QOL Medical, LLC | 27 | $508 |
| Braintree Laboratories, Inc. | 11 | $456 |
| Regeneron Healthcare Solutions, Inc. | 15 | $310 |
| Evoke Pharma, Inc. | 16 | $267 |
| Aimmune Therapeutics, Inc. | 7 | $258 |
| Janssen Scientific Affairs, LLC | 2 | $228 |
| E.r. Squibb & Sons, L.L.C. | 2 | $224 |
| Pfizer | 8 | $147 |
| Intra-sana Laboratories | 6 | $137 |
| Ipsen Biopharmaceuticals, Inc | 4 | $132 |
| Lilly USA, LLC | 2 | $114 |
| Bristol Myers Squibb | 5 | $95 |
| Organon | 1 | $87 |
| Intercept Pharmaceuticals, Inc. | 3 | $49 |
| Chiesi USA, Inc. | 3 | $48 |
| Vivus LLC | 2 | $37 |
| Boston Scientific | 2 | $32 |
| Concordia Pharmaceuticals Inc. | 2 | $32 |
| Romark Laboratories, LC | 1 | $24 |
| Sanofi | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Mauna Kea Technologies, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,360 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 1,032 | $578,185 |
| CreonLipase/Protease/Amylase | 446 | $413,435 |
| StelaraUstekinumab | 13 | $384,370 |
| Humira(Cf) PenAdalimumab | 25 | $161,902 |
| ZenpepLipase/Protease/Amylase | 118 | $123,635 |
| Dexlansoprazole DrDexlansoprazole | 335 | $71,551 |
| XifaxanRifaximin | 20 | $64,590 |
| IbsrelaTenapanor Hcl | 20 | $33,398 |
| NexiumEsomeprazole Magnesium | 55 | $26,923 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 153 | $24,356 |
| OzempicSemaglutide | 24 | $21,948 |
| DexilantDexlansoprazole | 57 | $16,920 |
| Pantoprazole Sodium | 2,214 | $16,913 |
| TrulancePlecanatide | 16 | $12,425 |
| Famotidine | 1,050 | $5,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $35,720 | $991,6211,478 claims |
| Johnson & JohnsonStelara | $994 | $384,37013 claims |
| Aimmune Therapeutics, Inc.Zenpep | $258 | $123,635118 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $11,630 | $77,01536 claims |
| Ardelyx, Inc.Ibsrela | $793 | $33,39820 claims |
| Braintree Laboratories, Inc.Sutab | $456 | $24,356153 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $13,817 | $16,92057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Philadelphia
- Kuchikala ReddyPhiladelphia$6.5M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.